{"id":"52f3258a-2d83-40ac-a6c4-46e98936ace0","arxiv_id":"2507.20714","paper_version":1,"verdict":"REJECT","confidence":"MODERATE","novelty_score":3.0,"correctness_risk":"high","formal_verification":"none","parameter_count":3,"one_line_summary":"A BERT-plus-random-forest pipeline fusing clinical notes and lab values reports 98-99% accuracy on PLCO prostate cancer staging, with an ablation suggesting text improves recall for intermediate stages.","lead":"The paper combines BERT text embeddings and random forest on lab numbers to classify prostate cancer stages from an NIH screening dataset, reporting 98 to 99 percent accuracy. The authors claim that adding clinical notes boosts recall for intermediate stages, but the results contain internal inconsistencies that need scrutiny.","discovery_kind":"new_application","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Table 7's ablation recall values are arithmetically impossible for the stated test-set class supports, so the paper's central claim that text lifts Class 2/3 recall is unsupported.","rationale":"The reader's REJECT verdict is correct, and the additional concern I identify does not change it. I agree with the reader that the paper's evaluation is not trustworthy, but I focus on a more decisive, internal problem: the ablation table that is supposed to demonstrate the central contribution contains recall values that are arithmetically incompatible with the paper's own test-set class counts. This does not require external knowledge of PLCO variable definitions; the inconsistency is visible from the manuscript alone. The reader's target-leakage concern about 'pros cancer diagdays' and 'pros dx psa gap' is plausible and should be checked, but it depends on the PLCO data dictionary and on assumptions about clinical timing. The ablation inconsistency is a direct, checkable defect. I also note that the paper reports no code, no hyperparameters, and conflicting accuracy figures (0.99 vs 0.90, 8769 vs 3882 samples), all of which compound the verification problem. The central claim about text complementarity is not merely under-supported; the reported evidence for it cannot be true as stated. Therefore the verdict remains REJECT.","tokens_in":16368,"tokens_out":8753,"duration_ms":100182,"concrete_test":"Re-run the three ablation configurations (numerical-only, textual-only, combined) on the exact 80/20 split described in Section 3.3, using the same PLCO rows and no SMOTE on the test set, and report per-class confusion matrices. Verify whether the Class 2 and Class 3 recalls equal those in Table 7 and whether the stated test-set supports (145 and 69) permit the reported values. If the recalls cannot be reproduced as integer true-positive counts, the multimodal improvement claim is invalid; a secondary check should also re-run the combined model after dropping 'pros cancer diagdays' and 'pros dx psa gap' to assess temporal leakage.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The paper's distinctive claim is that adding textual features lifts intermediate-stage recall (Class 2: 0.824 to 0.900; Class 3: 0.668 to 0.900), and this is the entire basis for the 'complementary value' conclusion. That claim rests on Table 7, which is labeled 'Test Set Recall Comparison for Ablation Study (No SMOTE)' and must therefore use the same 1,754-sample test set described in Table 5, with per-class supports of 4, 1536, 145, and 69. Under those supports, recall values must be of the form TP/145 for Class 2 and TP/69 for Class 3. A Class 2 recall of 0.824 would require 119.48 true positives out of 145, which is impossible; the nearest possible values are 119/145 = 0.8207 and 120/145 = 0.8276. A Class 3 recall of 0.668 requires 46.092 true positives out of 69, and 0.676 requires 46.644; neither is an integer. Even the reported combined recall of 0.900 for both Class 2 and Class 3 would require 130.5 and 62.1 true positives, respectively, unless the values are rounded from 130/145 = 0.897 or 131/145 = 0.903 and 62/69 = 0.899 or 63/69 = 0.913. No rounding of 0.824, 0.668, or 0.676 yields a possible integer count. Thus the central evidence that text improves intermediate-stage recall cannot be reproduced from the paper's own stated test-set composition. In addition, the numerical features include PSA values that are themselves components of AJCC staging, so high baseline accuracy is unsurprising; the only novel result is the text-based improvement, and that result is precisely what Table 7 fails to support.","agreement_with_reader":"partial"},"referee_report":{"model":"deepseek-v4-flash","summary":"This manuscript proposes a multimodal pipeline for prostate cancer staging on the PLCO dataset, combining BERT embeddings of clinical text with numerical lab/demographic features via PCA reduction, SMOTE, and a Random Forest classifier, with SHAP for interpretability. The central claim is that the combined model reaches a mean cross-validation accuracy of 98% and a test accuracy of 99% (macro AUC 0.9987), and that an ablation study shows textual features raise recall for intermediate stages (Class 2 from 0.824 to 0.900; Class 3 from 0.668 to 0.900). The paper also compares the proposed model with averaging and stacking ensembles and with prior published classifiers.","tokens_in":16710,"tokens_out":7708,"duration_ms":76685,"significance":"If correct, the paper would provide a simple, interpretable and computationally light alternative for prostate cancer staging in resource-constrained settings, with a concrete demonstration of complementary value from unstructured clinical text. The use of a public dataset, a transparent BERT+RF pipeline, and SHAP-based explanations are appropriate strengths. However, the reported evidence is not internally consistent: the headline accuracy changes from 0.99 to 0.90 in different sections, the sample size changes from 8,769 to 3,882, and the ablation recall table cannot be produced from the stated test-set class supports. The near-perfect results may also be inflated by diagnosis-derived numerical features whose temporal relation to the target label is not established. As a result, the paper's main claims are not currently supported.","major_comments":[{"comment":"The numerical feature set includes 'pros cancer diagdays' (Prostate Confirmed Cancer Diagnosis Days), 'pros dx psa' (most recent PSA before diagnosis), and 'pros dx psa gap'. These features are defined relative to the confirmed prostate cancer diagnosis and may therefore encode the outcome that the model is asked to predict. The manuscript does not state that these variables were measured before the AJCC stage was assigned, nor does it provide a temporal train/test split. Because the target is cancer stage, a model using diagnosis-day information can trivially achieve high accuracy, which would invalidate both the 0.99 accuracy claim and the modality comparison. The authors should re-run the experiments with features available at screening time only, or explicitly justify why these variables are not leakage.","section":"Section 3.1 and 3.2.1"},{"comment":"The central accuracy number is reported inconsistently: the Abstract and Table 5 report 99% test accuracy, Table 10 lists the proposed method as 0.99, but Sections 5.7 and 5.8 state twice that the proposed model's accuracy is 0.90. These are not rounding differences, and the reader cannot tell which result is the actual one. The sample size is also inconsistent: Section 3.2.1 states 8,769 effective samples and Table 5 sums to 1,754 test samples (20% of 8,769), while the Conclusion (Section 6.1) says the dataset comprises 3,882 samples. The empirical basis of the paper needs to be stated once, consistently, before any of the comparative claims can be assessed.","section":"Sections 5.4, 5.7, 5.8, and Table 10"},{"comment":"The ablation recall values in Table 7 are arithmetically incompatible with the test-set class supports reported in Table 5 (4, 1536, 145, 69). For example, Class 2 recall of 0.824 would require 119.48 true positives out of 145, and Class 3 recall of 0.668 would require 46.092 true positives out of 69; the nearest possible values are 119/145 = 0.8207, 120/145 = 0.8276, 46/69 = 0.6667, and 47/69 = 0.6812. The same problem affects the textual-only values 0.725 and 0.676 and the class-0 values 0.425 and 0.450 on support 4. Unless a different, undocumented test set was used, Table 7 cannot be derived from the paper's own data, so the central claim that text lifts Class 2/3 recall is unsupported.","section":"Table 7 and Section 5.5"},{"comment":"The ablation comparison is labeled 'No SMOTE', whereas the main pipeline described in Section 3.3 always applies SMOTE to the training folds. The manuscript does not explain whether the 'combined' column in Table 7 corresponds to the proposed model or to a variant trained without SMOTE. If the ablation deliberately removes SMOTE, then the claim in the Abstract and Section 5.5 that 'combined features' improve recall is not a statement about the proposed pipeline, and the comparison is not apples-to-apples with the test-set results in Table 5, which were obtained with SMOTE. This needs to be clarified and, more importantly, the ablation must be re-run on the actual proposed pipeline.","section":"Section 3.3 and Table 7"}],"minor_comments":[{"comment":"The text contains an unresolved placeholder 'See Table ??' when describing the extraction of 8,769 samples.","section":"Section 3.2.1"},{"comment":"The sentence 'while Principal Component 39 explains only 0.08Cumulative Variance Explained' is missing a word break or period; it should read '0.08. Cumulative Variance Explained'.","section":"Section 5.2"},{"comment":"The LaTeX citation command 'citefernandez2018smote' appears literally in the text instead of a rendered reference.","section":"Section 3.3"},{"comment":"Several entries are misformatted: the averaging model's Class 0 precision is given as '99' instead of 0.99, and the stacked model's Class 3 precision is given as '01' instead of 1.00.","section":"Table 9"},{"comment":"Some citations do not match their context: reference [5] is a dietary-pattern PCA meta-analysis, not a general PCA methods citation; reference [12] is a BPMRI bone-metastasis study but is cited as 'Castillo et al. using random forest on numerical biopsy data'; and reference [19] is a systematic review but is cited as 'Jose M. Castillo et al. using logistic regression and CNNs for MRI'.","section":"References"},{"comment":"The conclusion's sample size of 3,882 contradicts the 8,769 samples described in Section 3.2.1; the source of the discrepancy should be resolved or removed.","section":"Section 6.1"}],"recommendation":"reject","confidential_remarks":"I recommend rejection rather than major revision because the load-bearing issues are not local presentation fixes: the ablation table is numerically impossible under the paper's own test-set definition, the headline accuracy differs by 0.09 across sections, and the main feature set plausibly includes outcome-derived variables. Establishing the paper's claims would require a new data-preprocessing pipeline and a new set of experiments, which is outside the scope of a revision."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Quick take: the paper's one new result—that adding BERT text features to numerical lab data improves recall for intermediate prostate cancer stages—is not supported by its own reported numbers. Table 7's recall values are arithmetically impossible given the stated test-set class supports (4, 1536, 145, 69). 0.824 × 145 = 119.48 and 0.668 × 69 = 46.092; no integer true-positive count yields those decimals. Same for the textual-only 0.725 and 0.676. So the load-bearing ablation claim collapses.\n\nThat matters because the paper admits multimodal fusion is not new. The only fresh contribution is that ablation result, and it is internally inconsistent. The rest is a standard recipe: BERT embeddings, PCA to 39 components, SMOTE, Random Forest, SHAP, on the public PLCO dataset. The clinical goal—interpretable staging for low-resource hospitals—is legitimate, and the methodology section is clearly written. I give credit for that.\n\nBut the sloppiness is systemic. Accuracy is 0.99 in Tables 5 and 10, 0.90 in Sections 5.7–5.8. Sample size is 8,769 in the methods, 8,768 in the PCA output, 3,882 in the conclusion. The ablation is labeled 'No SMOTE' while the main pipeline uses SMOTE, and the test-set supports are not re-stated. No code, hyperparameters, or error bars.\n\nWorse, the numerical features include 'pros cancer diagdays' and 'pros dx psa gap', which may be unknown before the stage is assigned—that is potential target leakage. PSA levels themselves are inputs to AJCC staging, so the numerical-only accuracy is inflated by construction. The paper never states that these features were measured before staging.\n\nCitation pattern is adequate but shallow; a few self-citations, which is fine, but Table 10 compares across different datasets and modalities without caveat.\n\nWho should read this? Someone prototyping text-plus-numerics for cancer staging might get a general hint, but they'd need to redo the experiments completely. It is not a reliable reference.\n\nRecommendation: desk reject this version. The internal arithmetic alone is disqualifying. If the authors return with consistent reporting, explicit feature-temporality statements, external validation, and released code, the question is worth a fresh round of review.","headline":"The paper's only new result—text features improving intermediate-stage recall—is contradicted by its own impossible ablation numbers.","tokens_in":17337,"tokens_out":5689,"would_cite":false,"duration_ms":59989,"reading_group":"maybe","serious_thinker":"no","would_accept_peer_review":false},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"Fusing BERT-embedded clinical notes with numeric labs stages prostate cancer at 99 percent test accuracy.","keywords":["prostate cancer","multimodal fusion","BERT","Random Forest","SHAP","explainable AI","clinical notes","PLCO dataset"],"falsifier":"Run the same pipeline after removing 'pros cancer diagdays' and 'pros dx psa gap' from the numerical columns. If the combined-feature accuracy and the Stage III/IV recall advantage collapse toward the numeric-only numbers, the paper's central claim about multimodal fusion is unsupported.","tokens_in":16095,"feed_emoji":"🩺","tokens_out":6306,"duration_ms":65797,"temperature":0.7,"pith_summary":"The paper argues that a simple, interpretable machine-learning pipeline—BERT embeddings of free-text clinical notes concatenated with numeric lab values and classified by a Random Forest—can stage prostate cancer from PLCO trial records at 98% mean cross-validation accuracy and 99% test accuracy (macro AUC 0.9987). It claims the textual modality is not redundant: removing it drops recall for the intermediate Stage III and Stage IV classes from 0.900 to the 0.668–0.824 range. If correct, this matters because most clinical text remains underused in cancer staging, and the pipeline is cheap enough for resource-constrained hospitals while remaining fully explainable via SHAP. The central caveat is whether two numeric features (diagnosis-day and PSA-gap variables) are knowable before the stage is assigned.","feed_headline":"Text notes push prostate staging to 99% accuracy","feed_subtitle":"Fusing clinical notes with lab numbers lifts recall for mid-stage cancers, a common weak spot.","key_machinery":"The load-bearing mechanism is the feature-fusion pipeline: each patient's textual columns are concatenated into one string, embedded with BERT's [CLS] token, reduced with PCA to 39 components retaining 98.07% of variance, then concatenated with unscaled numeric columns, and the combined vector is fed to a Random Forest whose per-class weights are balanced and which is trained with SMOTE-augmented folds. The fusion is what lets the classifier exploit complementary signal: PSA screening levels dominate numerically, while the text-derived components contribute the patterns that lift recall for the intermediate stages.","core_discovery":"The paper's central claim is that multimodal fusion of BERT-derived textual features with numeric laboratory features yields a Random Forest classifier that reaches 0.99 test-set accuracy and 0.9987 macro-AUC on four AJCC prostate cancer stages in the PLCO dataset, with per-class recall of 1.00 (Stage II), 0.90 (Stage III), and 0.90 (Stage IV), and that this performance depends on the text modality: the ablation shows combined-feature recall for Stage III (0.900) and Stage IV (0.900) exceeds both the numerical-only (0.824, 0.668) and textual-only (0.725, 0.676) configurations. The authors frame this as a demonstration that a simple, transparent BERT+RF pipeline can be clinically useful rather than an exercise in complex architecture.","pith_inferences":["Editorial inference: a decisive check is to drop 'pros cancer diagdays' and 'pros dx psa gap'—both are built from the diagnosis timeline—and rerun the ablation; if the combined-feature advantage narrows, the textual lift is partly an artifact of temporal leakage.","Editorial inference: because the test set contains only four Stage I samples, the reported class-0 recall (0.50) has a wide confidence interval; a prospective cohort with more localized cancers would be needed to claim balanced multi-stage usability.","Editorial inference: the same BERT+RF fusion recipe could be lifted to other PLCO cancer arms (lung, colorectal, ovarian) where structured labs and narrative risk-factor text co-exist, turning this paper into a reusable template.","Editorial inference: if the temporal features are indeed post-diagnostic, then the practical recipe would be to replace them with screening-time PSA velocities, testing whether text still rescues intermediate stages."],"forward_implications":["A hospital that already stores structured lab panels plus free-text notes can reproduce this pipeline on a single workstation, without GPU training of a deep classifier.","If the accuracy holds prospectively, the model could serve as a decision-support triage tool that flags patients likely to be Stage III/IV and routes them to confirmatory imaging or biopsy.","SHAP rankings give clinicians a per-prediction feature attribution, making the model auditable in a way black-box imaging models are not.","The ablation result quantifies the value of unstructured notes: institutions that only build numeric models are leaving intermediate-stage recall on the table.","The stacking and averaging variants being weaker implies the simple concatenation is the right fusion choice for this data scale."],"supporting_citations":[{"why":"PLCO data dictionary and screening trial; supplies the 8,769 patient records and the feature set the whole experiment runs on.","marker":"[23]"},{"why":"BERT pre-trained model; provides the [CLS] embeddings for the textual clinical notes.","marker":"[3]"},{"why":"PCA; reduces the 768-dim BERT embeddings to 39 components, the step that makes fusion tractable and prevents overfitting.","marker":"[5]"},{"why":"SMOTE; generates synthetic minority-class samples during training, the mechanism that lets the classifier see balanced folds.","marker":"[6]"},{"why":"SHAP; the explainability layer that produces the feature attribution plots the paper relies on for interpretation.","marker":"[7]"},{"why":"Stratified K-Fold; defines the cross-validation scheme that yields the 98% mean accuracy claim.","marker":"[25]"},{"why":"Random Forest; the classifier whose balanced class weights and feature importances carry the label predictions.","marker":"[26]"},{"why":"scikit-learn; provides the cross_val_score, classification report, and metrics used for the headline numbers.","marker":"[27]"}],"fun_headline_variants":["Fusing notes and lab data lifts prostate cancer staging","Explainable AI fuses text and numbers for prostate cancer","BERT plus random forest hits 99% accuracy in prostate staging","Text notes boost recall for mid-stage prostate cancer","Simple multimodal AI improves prostate cancer classification"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The reported accuracy presupposes that the numeric features 'pros cancer diagdays' (Prostate Confirmed Cancer Diagnosis Days) and 'pros dx psa gap' are knowable before the stage is assigned; if they are computed from the diagnosis timeline or encode the outcome, the near-perfect results are leakage, not prediction.","fun_headline_variants_meta":{"raw":{"variants":["Fusing notes and lab data lifts prostate cancer staging","Explainable AI fuses text and numbers for prostate cancer","BERT plus random forest hits 99% accuracy in prostate staging","Text notes boost recall for mid-stage prostate cancer","Simple multimodal AI improves prostate cancer classification"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000155,"raw_usage":{"total_tokens":1171,"prompt_tokens":858,"completion_tokens":313,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":474,"completion_tokens_details":{"reasoning_tokens":238}},"tokens_in":474,"tokens_out":313,"duration_ms":4246,"temperature":1.0,"reasoning_tokens":238,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-06T13:19:00.114696+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Run the same pipeline after removing 'pros cancer diagdays' and 'pros dx psa gap' from the numerical columns. If the combined-feature accuracy and the Stage III/IV recall advantage collapse toward the numeric-only numbers, the paper's central claim about multimodal fusion is unsupported.","supporting_citations":[{"cited_title":"Accessed:, 2024","cited_arxiv_id":null,"evidence_quote":"PLCO data dictionary and screening trial; supplies the 8,769 patient records and the feature set the whole experiment runs on."},{"cited_title":"Dietary patterns derived from principal component analysis (pca) and risk of colorectal cancer: a systematic re- view and meta-analysis,","cited_arxiv_id":null,"evidence_quote":"PCA; reduces the 768-dim BERT embeddings to 39 components, the step that makes fusion tractable and prevents overfitting."},{"cited_title":"Smote for learning from imbalanced data: progress and challenges, marking the 15-year an- niversary,","cited_arxiv_id":null,"evidence_quote":"SMOTE; generates synthetic minority-class samples during training, the mechanism that lets the classifier see balanced folds."},{"cited_title":"Prediction of breast cancer re- currence in five years using machine learning tech- niques and shap,","cited_arxiv_id":null,"evidence_quote":"SHAP; the explainability layer that produces the feature attribution plots the paper relies on for interpretation."},{"cited_title":"Skcv: Strat- ified k-fold cross-validation on ml classifiers for pre- dicting cervical cancer,","cited_arxiv_id":null,"evidence_quote":"Stratified K-Fold; defines the cross-validation scheme that yields the 98% mean accuracy claim."},{"cited_title":"Deep learning hybrid models for multilingual cyberbully- ing detection: Insights from bangla and chittagonian languages,","cited_arxiv_id":null,"evidence_quote":"Random Forest; the classifier whose balanced class weights and feature importances carry the label predictions."},{"cited_title":"Scikit-learn,","cited_arxiv_id":null,"evidence_quote":"scikit-learn; provides the cross_val_score, classification report, and metrics used for the headline numbers."}],"review_version":1}